

For more information, contact Gary A. Ascani, CEO
gascani@banyanbio.com
386/462-2481

BANYAN APPOINTS TWO NEW BOARD MEMBERS

Gainesville, FL—April 3, 2007— Banyan Biomarkers, Inc., the leader in developing blood-test based, point-of-care diagnostic products to detect traumatic brain injury (TBI), has appointed Mel Rothberg and John N. Spencer, Jr. to the company's board of directors.

Rothberg has held executive positions in the medical device, information technology and biopharmaceutical fields throughout his career. Currently, he is chairman and chief executive officer of Advanced Processing and Imaging, Inc. of Deerfield Beach, Florida, and is chief executive officer of Rothberg Associates, a business and development firm in Weston, Florida. He has also been instrumental in forming Bio Florida's South Florida Bioscience Consortium, a collaborative regional effort that supports the development of the bioscience industry in South Florida. Rothberg holds a Masters in Business Administration from Nova Southeastern University and a Bachelor of Science degree in chemical engineering from Vanderbilt University.

Spencer has significant expertise in coordinating services to private and publicly held companies. He served for more than 38 years at Ernst & Young primarily in Boston and Atlanta, and was the market segment team leader for the firm's Southeast life sciences industry practice. Since his retirement in 2000, he has been active in Georgia's technology community, was awarded the Georgia Biomedical Partnership's first annual award for being a principal architect of the state's biomedical community and serves on five boards of directors. Spencer holds a Masters in Business Administration degree from Babson College and has completed Harvard Business School's Advanced Management Program. He received his Bachelor of Science degree from Syracuse University.

"We are honored to have Mel and Jack join us," said Banyan chief executive officer Gary Ascani, when announcing these appointments. "Both men bring a breadth and depth of experience in the biomedical field that will be invaluable to our work. With their help, Banyan will strengthen its ability to develop the tools instrumental in diagnosing and treating traumatic brain injuries."

--more--

New Banyan Board Members (page 2)

About Banyan Biomarkers

Banyan Biomarkers, with the aid of Department of Defense, congressional and National Institutes of Health funding, has identified the proteins, or biomarkers, that are released from the brain and make their way into the bloodstream after a traumatic brain injury, or TBI. Unlike other diagnostic

companies that are focused on disease detection, Banyan Biomarkers is developing products that will aid in the rapid diagnosis of TBI and injury to other vital organs.

Banyan was founded by Drs. Ron Hayes, Kevin Wang and Nancy Denslow in March 2002. Inspired by academic research at the University of Florida, Dr. Wang and Dr. Hayes established the Center for Traumatic Brain Injuries Studies and the Center for Neuroproteomics and Biomarkers within the Evelyn F. and William McKnight Brain Institute of the University of Florida. For more information about Banyan, visit the company's Web site at www.banyanbio.com.

###